Log In
Print this Print this

Leishmaniasis vaccine (MGN1331)

  Manage Alerts
Collapse Summary General Information
Company Mologen AG
DescriptionLeishmaniasis vaccine developed using MIDGE vectors encoding different Leishmania antigens
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationLeishmaniasis
Indication DetailsPrevent leishmaniasis infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today